Tuojie Biotechnology

Tuojie Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of novel small molecule drugs for oncology and autoimmune diseases. The company's research focus centers on the B-cell receptor signaling pathway, particularly targeting the MALT1 protein to treat various B-cell malignancies. Its lead candidate, TJ-M201, is a highly selective MALT1 inhibitor currently in Phase 1 clinical development for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Tuojie utilizes a structure-based drug design approach to develop a pipeline of differentiated therapies aimed at overcoming resistance to current treatments. The company is supported by leading venture capital investors and maintains a strong R&D presence in the Zhangjiang Hi-Tech Park.